Cormedix INC 10-Q quarterly reports

CorMedix Inc. announced a substantial increase in revenue and net income for the second quarter of 2026, primarily fueled by the integration of Melinta Therapeutics and robust sales of DefenCath.

CorMedix Inc. reported a significant increase in revenue and net income for Q1 2026, driven by the integration of Melinta Therapeutics and strong performance of DefenCath.

CorMedix Inc. reports a significant revenue increase in Q3 2025, driven by strong DefenCath sales and the strategic acquisition of Melinta Therapeutics, despite ongoing legal challenges and increased operating expenses.

CorMedix Inc. reported a dramatic surge in Q2 2025 revenue and net income, driven by DefenCath sales, and announced the strategic acquisition of Melinta Therapeutics for $300 million.

CorMedix Inc. reports a profitable first quarter in 2025, driven by the commercialization of DefenCath, with revenue reaching $39.1 million.

CorMedix Inc. reported its first commercial revenue in the third quarter of 2024, driven by the launch of its antimicrobial catheter lock solution, DefenCath.

CorMedix Inc. reported its first revenue of $806,119 following the commercial launch of DefenCath in the second quarter of 2024, while also experiencing increased operating expenses related to the launch.

CorMedix Inc. reported its first quarter 2024 financial results, highlighting increased operating expenses related to the upcoming commercial launch of DefenCath.